| |
Turnkey pharmaceutical manufacturing facilities and a 75% property tax exemption make expanding your bioscience business to Puerto Rico easier than ever. It's not what's next, it's where. Puerto Rico. 
|
|
Today’s Big NewsMay 20, 2024 |
|
Thursday, June 6, 2024 | 11am ET / 7am PT Assessment of antibody off-target reactivity is a regulatory requirement for clinical development. However, conventional screening methods are often ineffective in screening newer therapeutic modalities, and their predictive value for in vivo safety and toxicity is poor. Join us for a look at the new alternatives for success. Register now. 
|
|
| By Kevin Dunleavy At the American Thoracic Society international conference, one of the major themes is the advance of new therapies for COPD. On Monday, Sanofi and Regeneron had their answer to Amgen and AstraZeneca's presentation from the day before. |
|
|
|
By James Waldron The new year burst of biotech IPOs may have sputtered out months ago, but Rapport Therapeutics is a reminder that companies are still willing to test the waters of the public markets. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Kevin Dunleavy,Zoey Becker In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By Conor Hale A six-month trial showed that Boston Scientific’s pairing of modular, wireless implants for managing discordant cardiac rhythms—and correcting dangerous ones—could be a successful approach, and the devicemaker has its heart set on an FDA approval for the system in 2025. |
|
Wednesday, June 12, 2024 | 11am ET / 8am PT If you are a company developing gene therapies, don’t miss this opportunity to learn about containment and aseptic filling solutions – how to prepare for fill finish early and ensure products are ready to ship immediately upon approval, providing life-saving drugs to patients as quickly as possible. Register now. 
|
|
By Fraiser Kansteiner Riding high on its Daiichi Sankyo-partnered antibody drug conjugate (ADC) Enhertu—and banking on an approval for its next ADC contender datopotamab durextecan this winter—AstraZeneca is placing a big bet on the cancer-fighting technology as it blueprints a massive manufacturing investment in Asia. |
By James Waldron Three months after spending $4.3 billion on CymaBay Therapeutics for its primary biliary cholangitis med, Gilead Sciences has presented a fresh slice of data as a reminder of seladelpar’s potential while an FDA decision is pending. |
By Zoey Becker Pfizer's Wyeth subsidiary and licensee Puma Biotechnology sued AstraZeneca in 2021 for alleged patent infringement related to AZ's marketing of cancer blockbuster Tagrisso. |
By Nick Paul Taylor Endeavor BioMedicines has linked its Hedgehog inhibitor to improved lung function in a phase 2a idiopathic pulmonary fibrosis (IPF) study, sending a sonic pulse through a sector currently dominated by drugs that only slow the decline of the disease.. |
Fierce podcasts Don’t miss an episode |
| This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
|
Wednesday, June 19, 2024 |10am ET / 7am PT Join us on Monday, June 19, 2024 for one hour all about oral cyclic peptide drug development. Smaller breakthroughs in our own labs demonstrate results worth registering for. 
|
|
Whitepaper Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
Whitepaper Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
